Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.419
AS - Asia 6.358
EU - Europa 3.891
SA - Sud America 1.178
AF - Africa 190
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 22.049
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.404
SG - Singapore 2.729
HK - Hong Kong 1.363
RU - Federazione Russa 1.002
CA - Canada 920
BR - Brasile 895
CN - Cina 793
VN - Vietnam 648
IT - Italia 582
IE - Irlanda 557
SE - Svezia 527
DE - Germania 472
FR - Francia 205
IN - India 170
GB - Regno Unito 139
BD - Bangladesh 133
AR - Argentina 102
AT - Austria 85
UA - Ucraina 79
ID - Indonesia 76
IQ - Iraq 67
MX - Messico 66
ZA - Sudafrica 59
TR - Turchia 51
NL - Olanda 46
FI - Finlandia 45
EC - Ecuador 42
PH - Filippine 42
PK - Pakistan 42
JP - Giappone 39
ES - Italia 37
SA - Arabia Saudita 34
CO - Colombia 32
KR - Corea 31
MA - Marocco 29
VE - Venezuela 27
PL - Polonia 24
UZ - Uzbekistan 22
CL - Cile 20
PE - Perù 19
PY - Paraguay 19
RO - Romania 19
TN - Tunisia 17
ET - Etiopia 16
DK - Danimarca 12
DZ - Algeria 12
KE - Kenya 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
JO - Giordania 11
MY - Malesia 11
NP - Nepal 11
EG - Egitto 10
IL - Israele 10
BO - Bolivia 9
CH - Svizzera 9
OM - Oman 9
AU - Australia 8
KZ - Kazakistan 8
AL - Albania 7
CZ - Repubblica Ceca 7
GR - Grecia 7
LB - Libano 7
MU - Mauritius 7
PA - Panama 7
PT - Portogallo 7
DO - Repubblica Dominicana 6
TH - Thailandia 6
CR - Costa Rica 5
KG - Kirghizistan 5
KH - Cambogia 5
PS - Palestinian Territory 5
GE - Georgia 4
IR - Iran 4
JM - Giamaica 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
GA - Gabon 3
HN - Honduras 3
LY - Libia 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EE - Estonia 2
HU - Ungheria 2
LT - Lituania 2
ML - Mali 2
MM - Myanmar 2
NE - Niger 2
NZ - Nuova Zelanda 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BF - Burkina Faso 1
Totale 22.030
Salva come PNG Salva come JPEG
Città #
Singapore 1.395
Hong Kong 1.347
Ann Arbor 981
Fairfield 850
Toronto 775
Ashburn 717
Dublin 553
San Jose 496
Woodbridge 417
Wilmington 375
Houston 366
Chandler 362
New York 349
Frankfurt am Main 333
Dallas 311
Princeton 310
Cambridge 286
Seattle 262
Chicago 254
The Dalles 213
Santa Clara 212
Ho Chi Minh City 206
Hanoi 167
Beijing 162
Los Angeles 143
Altamura 140
Jacksonville 140
Lawrence 140
Lauterbourg 136
Milan 121
Moscow 86
São Paulo 83
Ottawa 81
San Diego 80
Council Bluffs 62
Buffalo 51
Nuremberg 51
Vienna 48
Andover 46
Jakarta 40
Orem 39
Shanghai 38
London 35
Falls Church 32
Helsinki 32
Hefei 31
Tokyo 31
Rio de Janeiro 29
Baghdad 28
Salt Lake City 28
Seoul 28
Guangzhou 24
Nanjing 24
Phoenix 24
Redmond 24
Brooklyn 22
Dearborn 22
Da Nang 21
Tashkent 21
Brasília 20
Dong Ket 20
Johannesburg 19
New Delhi 19
Warsaw 19
Atlanta 18
Dhaka 18
Haiphong 18
Norwalk 18
Rome 17
Florence 16
Montreal 16
Tampa 16
Cape Town 15
Chennai 15
Ankara 14
Belo Horizonte 14
Campinas 14
Columbus 14
Hải Dương 14
Lahore 14
Addis Ababa 13
Boardman 13
Denver 13
Elk Grove Village 13
Istanbul 13
Medellín 13
Paris 13
Poplar 13
Quito 13
Amsterdam 12
Curitiba 12
Delhi 12
Guayaquil 12
Jinan 12
Lima 12
Wuhan 12
Charlotte 11
Chengdu 11
Hangzhou 11
Jeddah 11
Totale 14.273
Salva come PNG Salva come JPEG
Nome #
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 318
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 308
Treatment of venous thromboembolism with tinzaparin in oncological patients 277
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 274
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 262
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 258
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 254
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 241
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 239
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 234
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 231
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 224
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 213
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 207
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 206
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 206
Thrombin generation predicts early recurrence in breast cancer patients 203
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 199
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 196
Clozapine-induced anemia: A case-report 190
Hemostatic biomarkers in occult cancer and cancer risk prediction 190
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 186
DOACs and “newer” hemophilia therapies in COVID-19: Reply 185
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 182
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 180
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 179
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 179
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 177
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 176
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 175
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 174
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 174
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 173
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 173
Laboratory haemostasis monitoring in COVID-19 172
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 169
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 169
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 168
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 168
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 168
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 167
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 166
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 165
V. Plasmaferesi terapeutica 161
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 159
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 159
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 159
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 158
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 158
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 158
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 154
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 154
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 153
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 152
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 151
Procoagulant mechanisms in tumour cells 150
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 149
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 148
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 148
The mechanisms of cancer-associated thrombosis 147
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 147
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 147
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 147
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 147
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 146
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 144
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 144
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 144
Molecular basis for the relationship between thrombosis and cancer 143
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 142
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 142
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 139
The Italian START-Register on anticoagulation with focus on atrial fibrillation 139
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 137
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 137
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 136
Venous thromboembolism in the hematologic malignancies 136
Type and dose of heparin in Covid-19: Reply 136
Cancer and venous thromboembolism 135
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 135
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 135
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 134
Hemostatic biomarkers in cancer progression 134
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 133
External validation of the DASH prediction rule: a retrospective cohort study 133
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 133
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 133
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 132
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 131
Microparticles in tumor progression 131
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 131
Risk of Venous Thromboembolism in Surgical Elderly Patients. 130
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study 130
La coagulopatia indotta da trauma 130
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 130
Edoxaban for the treatment of cancer-associated venous thromboembolism 129
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 128
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 127
Soluble stroma-related biomarkers of pancreatic cancer 127
Thrombosis in myeloproliferative neoplasms 126
Totale 16.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.425
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.425
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021319 0 0 0 0 0 0 0 0 0 0 189 130
2021/20221.563 160 169 178 95 64 76 93 102 69 98 110 349
2022/20232.027 370 568 182 133 95 404 7 90 95 17 41 25
2023/20241.469 26 52 20 18 227 403 259 44 243 20 5 152
2024/20254.320 303 731 200 166 354 74 289 96 414 610 329 754
2025/20268.838 655 606 828 948 924 524 1.317 586 772 676 1.002 0
Totale 22.732